Status:
UNKNOWN
the Pulmonary Safety of Antihepatitis C Treatment
Lead Sponsor:
Assiut University
Conditions:
Hepatitis C
Eligibility:
All Genders
18+ years
Brief Summary
pulmonary side effects of the new regimen of antihepatitis C
Detailed Description
Hepatitis C is a liver disease caused by the hepatitis C virus.The hepatitis C virus is a blood borne virus The most common modes of infection are through exposure to small quantities of blood, throug...
Eligibility Criteria
Inclusion
- 1\. HCV RNA positivity .
Exclusion
- Child C cirrhosis.
- Clinically manifest liver decompensation :ascites ,encephalopathy, wasting, hepatorenal syndrome.
- Serum albumin less than 2.8 g/dl,total serum bilirubin more than 3 mg/dl ,INR1.7 or more .
- absolute neutrophil counts \< 1500\\mm3 and\\or platelet less than 50,000/mm3.
- HCC except 6 months after concluding intervention aiming at cure with no evidence of activity by dynamic CT or MRI.
- Extrahepatic malignancy except after two years of disease\\disease free interval
- In lymphomas and chronic lymphatic leukemia can be initiated immediately after remission based on the treating oncologist's report
- Pregnancy or inability to use effective contraception
- Inadequately controlled diabetes mellitus (HbA1c\>9%)
- sever renal impairment in which creatinine clearance \< 30 ml\\min
- chronic lung diseases .
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04122066
Start Date
June 1 2020
End Date
December 1 2023
Last Update
March 30 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.